Live Breaking News & Updates on டோக்கியோ அடிப்படையிலானது டாகேடா
Stay updated with breaking news from டோக்கியோ அடிப்படையிலானது டாகேடா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tadataka Yamada, 1945-2021: Pioneer in drug development led global health at Gates Foundation geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains cash to support its pipeline of neurological disease drug candidates. Shares0 When Takeda Pharmaceutical and Ovid Therapeutics began working together four years ago, the partners aimed to share in the development of a drug with the potential to treat rare forms of epilepsy. The partners are ending the alliance, but Takeda leaves with full rights to a Phase 3 ready compound while Ovid gains $196 million to support its own pipeline of neurological disease drugs. ....